Purvalanol B

Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Purvalanol B is a CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively). It is inactive against Cdk4/cyclin D1 as well as several other protein kinases. Purvalanol B is a 2,6,9-trisubstituted purine that, at micromolar doses, inhibits the growth of parasites, including Plasmodium.Formal Name: 2-chloro-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]-benzoic acid. CAS Number: 212844-54-7. Synonyms: NG 95. Molecular Formula: C20H25ClN6O3. Formula Weight: 432.9. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 50 mg/ml, DMF:PBS (pH 7.2) (1:5): 0.2 mg/ml, DMSO: 30 mg/ml, Ethanol: 10 mg/ml. lambdamax: 210, 222, 284, 329 nm. SMILES: CC(C)N1C2=NC(N[C@H](C(C)C)CO)=NC(NC3=CC(Cl)=C(C(O)=O)C=C3)=C2N=C1. InChi Code: InChI=1S/C20H25ClN6O3/c1-10(2)15(8-28)24-20-25-17(16-18(26-20)27(9-22-16)11(3)4)23-12-5-6-13(19(29)30)14(21)7-12/h5-7,9-11,15,28H,8H2,1-4H3,(H,29,30)(H2,23,24,25,26)/t15-/m0/s1. InChi Key: ZKDXRFMOHZVXSG-HNNXBMFYSA-N.